B cell-targeted immunotherapy for type 1 diabetes: What can make it work?

Abdel Rahim A Hamad, Rizwan Ahmed, Thomas Donner, Georgia Fousteri

Research output: Contribution to journalArticle

Abstract

Immunotherapy has revolutionized treatment of cancers and autoimmune diseases. Bucking the trend, however, is type 1 diabetes (T1D), although it is one of best understood autoimmune diseases and individuals at genetic risk are identifiable with high certainty. Here we review the major obstacles associated with pan-B-cell-depletion using rituximab (RTX) and discuss the notion that B cell-directed therapy may be most effective as a preventive measure. We suggest that it will be more productive to aim at identifying and targeting autoreactive B cells rather than making adjustments to pan-B cell depletion and that non-conventional alternative therapies such as antibody blockade of FasL to bolster IL-10-producing Breg cells, which work successfully in mice, should be considered.

Original languageEnglish (US)
Pages (from-to)213-219
Number of pages7
JournalDiscovery medicine
Volume21
Issue number115
StatePublished - 2016

Fingerprint

Immunotherapy
B-Lymphocytes
Autoimmune Diseases
Regulatory B-Lymphocytes
Complementary Therapies
Cell- and Tissue-Based Therapy
Interleukin-10
Antibodies
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

B cell-targeted immunotherapy for type 1 diabetes : What can make it work? / Hamad, Abdel Rahim A; Ahmed, Rizwan; Donner, Thomas; Fousteri, Georgia.

In: Discovery medicine, Vol. 21, No. 115, 2016, p. 213-219.

Research output: Contribution to journalArticle

Hamad, Abdel Rahim A; Ahmed, Rizwan; Donner, Thomas; Fousteri, Georgia / B cell-targeted immunotherapy for type 1 diabetes : What can make it work?

In: Discovery medicine, Vol. 21, No. 115, 2016, p. 213-219.

Research output: Contribution to journalArticle

@article{2daae1e1cdd14b6fbed4d03827fe8cce,
title = "B cell-targeted immunotherapy for type 1 diabetes: What can make it work?",
abstract = "Immunotherapy has revolutionized treatment of cancers and autoimmune diseases. Bucking the trend, however, is type 1 diabetes (T1D), although it is one of best understood autoimmune diseases and individuals at genetic risk are identifiable with high certainty. Here we review the major obstacles associated with pan-B-cell-depletion using rituximab (RTX) and discuss the notion that B cell-directed therapy may be most effective as a preventive measure. We suggest that it will be more productive to aim at identifying and targeting autoreactive B cells rather than making adjustments to pan-B cell depletion and that non-conventional alternative therapies such as antibody blockade of FasL to bolster IL-10-producing Breg cells, which work successfully in mice, should be considered.",
author = "Hamad, {Abdel Rahim A} and Rizwan Ahmed and Thomas Donner and Georgia Fousteri",
year = "2016",
volume = "21",
pages = "213--219",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "115",

}

TY - JOUR

T1 - B cell-targeted immunotherapy for type 1 diabetes

T2 - Discovery medicine

AU - Hamad,Abdel Rahim A

AU - Ahmed,Rizwan

AU - Donner,Thomas

AU - Fousteri,Georgia

PY - 2016

Y1 - 2016

N2 - Immunotherapy has revolutionized treatment of cancers and autoimmune diseases. Bucking the trend, however, is type 1 diabetes (T1D), although it is one of best understood autoimmune diseases and individuals at genetic risk are identifiable with high certainty. Here we review the major obstacles associated with pan-B-cell-depletion using rituximab (RTX) and discuss the notion that B cell-directed therapy may be most effective as a preventive measure. We suggest that it will be more productive to aim at identifying and targeting autoreactive B cells rather than making adjustments to pan-B cell depletion and that non-conventional alternative therapies such as antibody blockade of FasL to bolster IL-10-producing Breg cells, which work successfully in mice, should be considered.

AB - Immunotherapy has revolutionized treatment of cancers and autoimmune diseases. Bucking the trend, however, is type 1 diabetes (T1D), although it is one of best understood autoimmune diseases and individuals at genetic risk are identifiable with high certainty. Here we review the major obstacles associated with pan-B-cell-depletion using rituximab (RTX) and discuss the notion that B cell-directed therapy may be most effective as a preventive measure. We suggest that it will be more productive to aim at identifying and targeting autoreactive B cells rather than making adjustments to pan-B cell depletion and that non-conventional alternative therapies such as antibody blockade of FasL to bolster IL-10-producing Breg cells, which work successfully in mice, should be considered.

UR - http://www.scopus.com/inward/record.url?scp=85007316346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007316346&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 213

EP - 219

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 115

ER -